Your browser doesn't support javascript.
Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation.
Li, Hong-Tian; Cheng, Zhi-Hao; Huang, Yong-Ying; Lv, Xi-Lin; Zhou, Yu-Bo; Dong, Erdan; Liu, Jian-Meng.
  • Li HT; Institute of Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive Health, Peking University Health Science Center, No 38, Xueyuan Road, Haidian District, Beijing 100191, China.
  • Cheng ZH; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China.
  • Huang YY; Institute of Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive Health, Peking University Health Science Center, No 38, Xueyuan Road, Haidian District, Beijing 100191, China.
  • Lv XL; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China.
  • Zhou YB; Institute of Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive Health, Peking University Health Science Center, No 38, Xueyuan Road, Haidian District, Beijing 100191, China.
  • Dong E; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing 100191, China.
  • Liu JM; Institute of Reproductive and Child Health, National Health Commission Key Laboratory of Reproductive Health, Peking University Health Science Center, No 38, Xueyuan Road, Haidian District, Beijing 100191, China.
Innovation (Camb) ; 1(2): 100028, 2020 08 28.
Article in English | MEDLINE | ID: covidwho-720752
ABSTRACT
Since the outbreak of COVID-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment. However, a public health emergency calls for a balance between gathering sound evidence and granting therapeutic access to promising trial drugs as widely as possible. In an electronic survey, we found that 3.9% of the participants preferred to receive an unproven trial drug directly in the hypothetical scenario of mild COVID-19 infection. This percentage increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe and extremely severe infection, respectively. Our survey indicates a likelihood of substantial receptivity of trial drugs among actual patients in severe conditions. From the perspective of deontological ethics, a trial can only be approved when potential benefits of the investigational treatment are presumed to outweigh risks, so compassionate or off-label use of investigational therapies merits evaluation.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Innovation (Camb) Year: 2020 Document Type: Article Affiliation country: J.xinn.2020.100028

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Innovation (Camb) Year: 2020 Document Type: Article Affiliation country: J.xinn.2020.100028